Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Cadonilimab Neoadjuvant Therapy for High-Risk Localized or Locally Advanced Renal Cell Carcinoma
ChiCTR2300075836Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2023
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and cadonilimab in renal cell carcinoma (RCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective response rate. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
lenvatinibcadonilimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2300075836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075836.